StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
October 4, 2016 9:01 AM
RBC Capital analyst Simos Simeonidis said he likes Sarepta Therapeutic (NASDAQ: SRPT) EU/LatAm partnership with Summit (NASDAQ: SMMT), as it ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Rumors
Next Articles
Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal
October 4, 2016 1:38 PM
Oppenheimer Keeps Summit Therapeutics (SMMT) at 'Outperform' Amid New DMD Deal (SRPT)
October 4, 2016 9:31 AM
Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'
October 4, 2016 9:13 AM
Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal
October 4, 2016 8:56 AM
Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer
October 4, 2016 8:44 AM
Sarepta (SRPT), Summit Therapeutics (SMMT) Enter Licensing Agreement for Utrophin Modulator Pipeline
October 4, 2016 7:02 AM
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 4, 2016 7:00 AM
Sarepta (SRPT) PT Raised to $58 at Jefferies
October 3, 2016 6:42 AM
